Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: A multivariate analysis

Annals of Surgical Oncology

Volumn 7, Issue 4, 2000, Pages 305-311

  Bhatavdekar, Jyotsna M ^a   Patel, Devendra D ^a   Shah, Neelam G ^a   Vora, Hemangini H ^a   Suthar, Tejal P ^a   Chikhlikar, Priya R ^a   Ghosh, Nandita ^a   Trivedi, Trupti I ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Bcl 2; P53; Prognostic factor; Stage II and stage III breast cancer

Indexed keywords

HERMES ANTIGEN; KI 67 ANTIGEN; PROLACTIN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; VON WILLEBRAND FACTOR;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034039777     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-000-0305-5     Document Type: Article

References (30)

1. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-38.
2. Gasparini G, Gullick WJ, Bevilacqua P, et al. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 1992;10:686-95.
3. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47.
4. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995; 60:54-60.
5. Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-9.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
7. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993;10:302-13.
8. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of breast cancer metastasis. Cell 1994;79: 185-8.
9. Weikel W, Beck T, Mitze M, Knapstein PG. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 1991;18: 149-54.
10. Bhatavdekar JM, Giri DD, Shah NG, et al. Prolactin in advanced breast cancer: an Indian experience. Breast Dis 1990;3:199-204.
11. Bhatavdekar JM, Shah NG, Balar DB, et al. Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer 1990;65:2028-32.
12. Patel DD, Bhatavdekar JM, Chikhlikar PR, et al. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 1996;62:86-92.
13. Bhatavdekar JM, Patel DD, Shah NG, et al. Role of prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur J Surg Oncol 2000 (In press).
14. UICC TNM classification of malignant tumors. Breast (ICD-O THE-174). In: Seller AH, ed. UICC Technical Report Series. 1st ed. Geneva, Switzerland, 1980:51:7.
15. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
16. Bhatavdekar JM, Patel DD, Chikhlikar PR, et al. Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol 1998;5:495-501.
17. Norusis MJ. SPSS (SPSSfor Windows: Base System User's Guide, Release 6.0). Chicago: SPSS Inc., 1993.
18. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-15.
19. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein co-expression: value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995;221:706-20.
20. Han S, Yun I-J, Non D-Y, Choe K-J, Song S-Y, Chi JG. Abnormal expression of four novel molecular marker represents a highly aggressive phenotype in breast cancer: immunohistochemical assay of p53, nm23, erbB-2, and cathepsin D protein. J Surg Oncol 1997;65:22-7.
21. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991;164:75-81.
22. Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
23. Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred DC. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat 1993;27:95-102.
24. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
25. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia: W.B. Saunders, 1995:206-32.
26. Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-63.
27. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis. Cancer 1995;75:1320-26.
28. Wintzer H-O, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991;67:421-8.
29. Locker AP, Birrell K, Bell JA, et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol 1992;18:224-9.
30. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994;57:822-9.